Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
|
|
Associated Press (10.21.09) - Thursday, October 22, 2009
Mike Stobbe
ACIP avoided stating a preference for either vaccine. However, officials noted that Cervarix is effective against cervical cancer caused by two HPV strains, while Gardasil performs the same function while providing additional protection against genital warts. Some members said they considered that extra protection important.
Genital warts have "an enormous impact on relationships and self-esteem," said Dr. James Turner, a non-voting ACIP liaison representing the American College Health Association and executive director of student health at the University of Virginia.
Cervarix and Gardasil are both administered in three injections costing a total of $385 and $390, respectively. Some cost-effectiveness studies suggest that Cervarix should be priced about $100 lower, since it does not prevent genital warts, said Harrell Chesson, a CDC economist. Some physicians and doctors may prefer Cervarix because it costs slightly less, some experts said.
Compared to Gardasil, more women who received Cervarix reported pain, redness, and swelling at the injection site, possibly due to a new kind of adjuvant used to boost the immune response, ACIP members said. No studies have been conducted to see whether Cervarix and Gardasil are interchangeable in subsequent doses for cervical cancer protection.
091022
AD091816
Copyright © 2009 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.